Cantor Fitzgerald Reaffirms "Overweight" Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)
Cantor Fitzgerald reissued their overweight rating on shares of Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) in a report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Eledon Pharmaceuticals’ FY2023 earnings at ($1.83) EPS. Eledon Pharmaceuticals Stock Down 0.4 % Shares of NASDAQ:ELDN opened at $2.24 on Monday. The stock has a […]